Clinical Trial

Open Label, Safety and Efficacy Study of QRX003 Lotion in Subjects With Netherton Syndrome

Recruiting Phase 2/3
View on ClinicalTrials.gov →
Record status
This record was last updated April 2, 2025 (before its estimated December 30, 2025 completion). Its status may not reflect the trial's current state.
Summary
To assess the safety, tolerability, and efficacy of QRX003 lotion (4%) when added to standard of care treatment regimen, including systemic therapy in subjects with Netherton syndrome
Protocol Amendment History 4 amendments
This ClinicalTrials.gov record has been amended 4 times since 2023-03-16; most recent amendment 2025-03-28.
Trial Details
NCT Number NCT05789056
Lead Sponsor Quoin Pharmaceuticals
Conditions Netherton Syndrome
Enrollment 20 participants
Start Date 2023-03-14
Primary Completion 2025-12-30 (estimated)
Study Completion 2025-12-30 (estimated)
Updated on ClinicalTrials.gov 2025-04-02